Antigen Cncer 125 Expression Of The Diagnostic Method Of Early Ovarian Cancer Stage

BACKGROUND:Consultant gynecologic oncologists ELISA laboratory from the regional Register Cancer Center assisted community gynecologists'CA 125 test after diagnosis method for early ovarian cancer when they were invited. For this report, the study evaluated the performance CA125 effects of early stage on diagnosis outcome METHODS: The hospital files from 227 diagnosed for epithelial ovarian cancer between 2005-2009 of ConakryJilin2, ChinoGuineans, Africasia were abstracted. The diagnosis results were analyzed 4 for weak reaction ELISA; 154 for moderate; 27 for strong at the patients according to the clinicians examination by ELISA for diagnosis and SSP 15.00, Epi-Info6 analyses with univariate and multivariate Cox regression. RESULTS:Method was performed on 178 Bethune (BN) patients, and 7 Conakry (CY). ELISA Bethune followed diagnostically guidelines more strictly compared with Conakry,8CY(18.60%) vs.37BN(20.10%);[P=0.01]ⅠA-ⅠB stage; 8CY(18.20% vs. 30 BN(16.30%); [P=0.003]ⅡA-ⅡB stage,within 27 CY(62.79%) vs. 117 BN(63.58%); [P=0.02]ⅠC～ⅡC stage. Patients tumor were stratified according to early stageⅠwith 5-year overall survival rate was 96% versus 80%; (P=0.03) for patients disease and 76% versus 60%, (P=0.02) for stageⅡwho underwent peripheral blood ELISA CA125 Bethune and Conakry diagnosis. The hazards ratio was 0.79 (95% confidence interval [95%CI],0.61-1.03; adjusted for patient age, stage, type of hospital, when patients age 77 years were excluded, the hazards ratio fell to 0.71 (95% CI,0.54-0.94) in multivariate analysis. CONCLUSIONS:An early diagnosis ovarian cancers by ELISA CA125 occurred more often according to laboratory guidelines, tumor removal more often was complete, and survival improved.Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Jilin University Medical Center Normal Clinical, Bethune, The ChinoGuineansCD 10183, ID 9200873101 ObjectiveIn the past 20 years the diagnosis have made a great effort a variety of tumor makers in clinical widely used. The guide clinical laboratory with early prevention has effective important ovarian cancer significance. The recent past 3 years showing an improvement of infrastructure and methods of diagnosis that there was an increased demand on CA125 assay over the past 5-years, particularly in the last 3 years compared of data variety early diagnosis method clinic of patients of early ovarian cancer. The retrospective study was designed performance as assessed by the area under the receiver biomarker cancer antigen CA125 alone of panel to correctly identify women significantly greater and performance with early ovarian cancer chinoguineans.MethodsThe biochemical ELISA technique, a high molecular weight glycoprotein, was measured in sera from patients with the most common cause of cancer death among gynecologic tumors stages (ⅠandⅡ) in the benign worldwide. For biomarker panel Bethunedonka (BD) in surgical resection specimens and control group, blood sample with early ovarian cancer clinical data underwent respective examination monoclonal CA-125 albumins with ovarian cancer diagnosed kit blood from March 2005 January 1 to 2009 December 31, the Second Jilin hospital, Clinical Bethune of Medical Science (BN) of International Exchange Center Jilin University, Changchun, Jilin, China and Registered Cancer Center, National Hospitals Donka, Gamal Abdel Nasser University, Conakry(CY), West Africa. Guinea.The ELISA data by In Vitro (protocol No.1820/ub90504A) kit sensitivity color reagent were purchased from a new biological Technology Co., Ltd, United States, and Alpha Diagnostic Intl.We observed high CA125 efficiencies in the early ovarian cancer (stageⅠ-Ⅱ) and in ELISA using low peripheral blood concentrations with the absence of significant cell viability impairment. Early ovarian cancer has evolved as a superior method for CA125 into peripheral blood cells, CA125 was expressed in 4 for weak reaction ELISA; 154 for moderate; and 27 for strong at the patients as reported in the literature.The expressing verified the results with the Gene Bank expression database analyzed cancer cells instability with this ELISA type, such as relevance of ovarian cancer stage I-II.Statistical analysis Methods:Two independent statisticians from program Epi-Info and SPSS15.0 calculate statistic analyzed the data; the age average (mean±SE) of patients will be evaluated. Significant difference was that p<0.05 which represented all probability values lower than 0.05. The study was performed encompassing the critical issues associated with expression efficiency, to standardize a CA125 protocol for use in early ovarian cancer ELISA schedules. Through the peripheral blood of patients with early ovarian cancer free DNA for qualitative research to explore new treatment can be used early diagnosis stage and efficacy of the method of monitoring. CA125 was used as an antigen cancer to optimize peripheral blood by early ovarian cells by diagnosis the expression of the reporter tumor gene analysis for confirmation of the optimized loading parameters.ResultsThe efficiency of this delivery system was assessed using CA125 peripheral blood in stimulating antigen specific peripheral blood cell responses in early ovarian stage of healthy individuals. The peripheral blood + antigen specific early ovarian cells responses were generated recognizing CA125 peripheral blood plasma and also early ovarian cancer cell lines endogenously expressing CA125. This study has identified CA125 specific early ovarian cells responses in healthy patients, allowing further investigation into the potential for its use as a stage I and II in ovarian cancer ELISA. Furthermore, the use of antigen cancer CA125 expressed with peripheral blood ovaries is a promising strategy for the delivery of CA125in the generation of antigen-specific early ovarian cell responses.Early diagnostic efficiency are undoubtedly the major priorities for achieving long-term reduction of mortality due to ovarian cancer the hypothesis that early ovarian cancer may be detectable up to many years prior clinical presentation and that if effective diagnosis for early stage disease were achieved with an accuracy of 80% or more, mortality would be halved. The positivity of serum concentrations of CA125 expression are elevated (i.e.>35 U/ml) in 163 blood of patients with early stage disease. The CA125 expressions in patients with varied FIGO clinical stage were different. The data case cohort (overall and by disease stage) median age (range) of the (n=227) was 49.89(18-77) years (mean±SE,49.89±14.96) of age on plasma biomarker concentration identified (Spearman's rank correlation,0.0004. p< 0.05). A- Tumor type was identified and FIGO clinical stage by FIGO nomenclature Rio de Janeiro 1998, ACS Cancer Facts & Figures,2007 presented of early stage cohorts:⊥The CA125 expressions in patients with 146 cases (64.31%) IIB stage disease was much highest than in patients both with 12 (<35 U/ml) IC～IIC positive, the CA125 expression correlated the types, were significantly of IB to IIB, (0.496. p<0.05); and IIC (0.431,p<0.05).⊥IB-IIB compared to IC-IIB, P= 4.375E-05,# IIC compared to IC-IIB, P= 0,013⊥IB-IIB* compared to IA, P= 0,496,# IIC compared to IA, P= 0,431Patient's commonly situation of early ovarian cancer, the significance difference was *IB～IIB compared to IC-IIB, P= 4.375E-05,# IIC compared to IC-IIB, P= 0,013.⊥The CA-125 expressions elevated (i.e.□35 U/ml) in 22 cases (11.95%) in patients with I stage, was lowest than in 99(53.80%) of II stage.B-The group Controls and early ovarian cancer⊥In biomarker (n= 185{43.59±13.12} Cases) and (n=227{49.89±14.96}, Cases). The positives (n=175{40.87±11.48}, group compared falsies positives (n=6{27.09±10.14}). The significant differences biomarker plasma concentrations were significantly greater within 154(4CY+150BN) with 38.60±15.12 average (0.44, p< 0.05) moderate,27(1CY+26BN), 35.08±10.08 for strong,4 (2 CY and 2 BN)= 17.03±5.08 for weak reaction at patients and early ovarian cancer positively of date in Clinical patients 224(0.0003, p<0.05) of CA125 alone.⊥High levels (<35 U/ ml) were found in 4 cases of 227 patients with active ovarian cancer but in 181 (79.73 %) Bethunedonka (BD) patients who had positive of cases.⊥The tumor size on biomarker CA-125 plasma concentration was highly than in cells tumor>2 cm (177.24%) i.e 97.62% of the ovarian cells tumor<2 cm, plasma concentration was no significantly with tumor size, (0.019,p<0.05)⊥Anatomical seat 18-37 ages were usually much affected,63 cases i.e.7 cases tumors associated, (0.299, p<0.05). Histological diagnosis by age and anatomical areas (0.299, p<0.05) compared to anatomical areas by age (0.0006, P<0.05).C- Correlation between CA-125 protein and clinicopathological features of the patients of early ovarian cancer.⊥The housewives are the most affected layer less than urban women to increase with processing,62.71%, with 142.37% of cases respectively. Compared with ovarian tumors unilateral or bilateral with other tumor,72.88%,27.11% of the cases registered. There were no statistical significantly difference correlates in profession (0.032, p<0.05) and age> 58 old (0,286, p<0.05) compared to education level (0.009, p< 0.05) with CA125A cancer antigen positively. CA125 positive expressing was seen in 17 of patients who get married before 18 old and 146(78.91%) after 18 years old; high than the age group 38 to 57 57.62%, and the age group below 18 years represents 6.77% respectively. Compared to married,67.79% and multiparous,76.27%patients. The CA125 expression were also no statistical significantly difference inthe parity (0.073, p<0.05), complaints (p=0.091, p<0.05) and in age marriage (>18 old years,0.106,p<0.05) for cohorts.D-According to the variety histopathological diagnosis clinic in early stage4-CA125 was expressing much than the teratoma (417.62%) with cystadenocarcinome, endometrial adenocarcinoma, and non ovarian adenocarcinomas.4 In five (5) past years, the data in our study were further analyzed with types and detected in 14(6.16%) cases with endometrioid carcinoma with 5-year relative diagnosis estimates increasing from 6(42.85%) in 2005-2007 to 8(57.14%) in 2008-2009.⊥We in 4(2.12%) clear cell carcinoma were diagnosed. The significant difference was in 2005, (0.03, P<0.05) and 2007, (0.02 p<0.05) diagnosis. In cystadenocarcinoma (n=40), serous,(n=26), mucinous(n=13), Brenner tumor and borderline(n=12), Adenocarcinoma(n 5), Leiomyoma et ascite carcinomatous(n =29). Cysts and teratoma tumors(n = 41) with carcinoma(n = 20), mixed type (mixed, n = 25). Tumor typing was no significantly with CA125.⊥The greatest frequency was observed in 2005 which is lower than that in 2007 diagnosis 25.06% vs. (37.62%), respectively. Almost,157(145.92%) cases were detected in the recent past 3 years.⊥Of those patients,144 cases underwent surgical procedures.5 had ovarian cancers,3 had adenocarcinoma of unknown origin,28 had benign tumors,8 had fibroids, and 3 had no abnormalities.Using ELISA normal distribution statue to classify the measurements a sensitivity of 81.49 % and 71.80% specificity was achieved when classifying normal and cancerous samples. Also, a sensitivity of specificity was obtained when classifying patients as either being in a high risk group or low risk group of developing ovarian cancer. The results gained from this PhD thesis should be taken into consideration when designing future CA125 ELISA strategies, to combat one of the leading causes of cancer mortality in women, early ovarian cancer.ConclusionThe ovaries are small female reproductive organs that reside in the pelvis. The ovary makes female hormones reproduction system. Diagnosis of disease in early stages can reduce the high mortality rate of ovarian cancer and treat of disease in advanced stages. CA125 is not a novel strategy to express peripheral blood and a strong expression simultaneously in ovaries cells earlier. The functional capacity of this system requires further monitoring before it can be considered for investigation clinical use.